Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study

References

• Even-Sapir E, Israel O. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. Eur J Nucl Med Mol Imaging 2003; 30(Suppl 1)S65–S81
   PubMed Web of Science ®Google Scholar
• Schiepers C, Filmont J E, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; 30(Suppl 1)S82–S88
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Verhoef G, Mortelmans L. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003; 30(Suppl 1)S97–S105
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Juweid M E, Wiseman G A, Vose J M, Ritchie J M, Menda Y, Wooldridge J E, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652–4661
   PubMed Web of Science ®Google Scholar
• Wirth A, Seymour J F, Hicks R J, Ware R, Fisher R, Prince M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002; 112: 262–268
   PubMed Web of Science ®Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Armitage J O, Weisenburger D D, Hutchins M, Moravec D F, Dowling M, Sorensen S, et al. Chemotherapy for diffuse large-cell lymphoma – rapidly responding patients have more durable remissions. J Clin Oncol 1986; 4: 160–164
   PubMed Web of Science ®Google Scholar
• Israel O, Mor M, Epelbaum R, Frenkel A, Haim N, Dann E J, et al. Clinical pretreatment risk factors and Ga-67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non-Hodgkin lymphoma. Cancer 2002; 94: 873–878
   PubMed Web of Science ®Google Scholar
• Janicek M, Kaplan W, Neuberg D, Canellos G P, Shulman L N, Shipp M A. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15: 1631–1637
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Coleman M, Leonard J P, Kuji I, Zoe H, Goldsmith S J. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43: 1018–1027
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte M F, Najjar F, Paulus P, Rigo P, et al. Persistent tumor 18f-fdg uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85: 613–618
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1356–1363
   PubMed Web of Science ®Google Scholar
• Mikhaeel N G, Hutchings M, Fields P A, O'Doherty M J, Timothy A R. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514–1523
   PubMed Web of Science ®Google Scholar
• Haioun C, Itti E, Rahmouni A, Brice P, Rain J D, Belhadj K, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376–1381
   PubMed Web of Science ®Google Scholar
• Zijlstra J M, Hoekstra O S, Raijmakers P G, Comans E F, van der Hoeven J J, Teule G J, et al. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2003; 123: 454–462
   PubMed Web of Science ®Google Scholar
• Jaffe E S, Harris N L, Stein H, Vardiman J W. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon 2001
   Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Tilly H, Mounier N, Lederlin P, Briere J, Dupriez B, Sebban C, et al. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. J Clin Oncol 2000; 18: 1309–1315
   PubMed Web of Science ®Google Scholar
• Rothman K J, Boice J D. Epidemiologic Analysis with a Programmable Calculator. Epidemiology Resources Inc, Boston, MA 1982
   Google Scholar
• StatXact Statistical Software for Exact Nonparametric Inference. Cytel Software Corporation, Cambridge, MA 2004, Release 6.2. 2005
   Google Scholar
• Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo J M, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL Classification. Ann Oncol 1998; 9: 849–855
   PubMed Web of Science ®Google Scholar
• Park Y H, Kim S, Choi S J, Ryoo B Y, Yang S H, Cheon G J, et al. Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone. Ann Oncol 2005; 16: 1401–1402
   PubMed Web of Science ®Google Scholar
• Israel O, Mekel M, Bar-Shalom R, Epelbaum R, Hermony N, Haim N, et al. Bone lymphoma: 67Ga scintigraphy and CT for prediction of outcome after treatment. J Nucl Med 2002; 43: 1295–1303
   PubMed Web of Science ®Google Scholar
• Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, et al. 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging 2005; 32: 749–756
   PubMed Web of Science ®Google Scholar
• Freudenberg L S, Antoch G, Schutt P, Beyer T, Jentzen W, Muller S P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 325–329
   PubMed Web of Science ®Google Scholar
• Chajari M, Lacroix J, Peny A M, Chesnay E, Batalla A, Henry-Amar M, et al. Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography?. Eur J Nucl Med 2002; 29: 380–387
   Google Scholar
• Palumbo B, Sivolella S, Palumbo I, Liberati A M, Palumbo R. 67Ga-SPECT/CT with a hybrid system in the clinical management of lymphoma. Eur J Nucl Med Mol Imaging 2005; 32: 1011–1017
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, Pedersen L M, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52–59
   PubMed Web of Science ®Google Scholar
• Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 22–28
   PubMed Web of Science ®Google Scholar
• Bartold S P, Donohoe K J, Fletcher J W, Haynie T P, Henkin R E, Silberstein E B, et al. Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. Society of Nuclear Medicine. J Nucl Med 1997; 38: 990–994
   PubMed Web of Science ®Google Scholar
• Bombardieri E, Aktolun C, Baum R P, Bishof-Delaloye A, Buscombe J, Chatal J F, et al. FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2003; 30: BP115–BP124
   PubMed Web of Science ®Google Scholar